patient advocate foundation copay relief

Tell your healthcare provider right away if you develop any symptoms of infection during treatment, including fever of 100.4☏ (38☌) or higher, cough, chest pain, tiredness, shortness of breath, painful rash, sore throat, pain during urination, or feeling weak or generally unwell. Your healthcare provider will check you for symptoms of infection before and during treatment.

Infections. EPKINLY can cause serious infections that may lead to death.

These may be symptoms of CRS or neurologic problems.ĮPKINLY can also cause other serious side effects, including: Your healthcare provider may temporarily stop or completely stop your treatment with EPKINLY if you develop CRS, neurologic problems, or any other side effects that are severe.ĭo not drive or use heavy or potentially dangerous machinery if you develop dizziness, confusion, tremors, drowsiness, or any other symptoms that impair consciousness until your symptoms go away. Your healthcare provider will monitor you for symptoms of CRS and neurologic problems during treatment with EPKINLY, as well as other side effects, and treat you if needed. Tell your healthcare provider right away if you develop any symptoms of neurologic problems, including trouble speaking or writing, confusion and disorientation, drowsiness, tiredness or lack of energy, muscle weakness, shaking (tremors), seizures, or memory loss.ĭue to the risk of CRS and neurologic problems, you should be hospitalized for 24 hours after receiving your first full dose of EPKINLY on day 15 of cycle 1. Your healthcare provider may refer you to a healthcare provider who specializes in neurologic problems. Neurologic problems may happen days or weeks after you receive EPKINLY. EPKINLY can cause serious neurologic problems that can be life-threatening and lead to death.

Your healthcare provider will decide if you need to receive medicine to help reduce your risk of CRS with future cycles. Before each dose in cycle 1, you will receive medicines to help reduce your risk of CRS. If your dose of EPKINLY is delayed for any reason, you may need to repeat the step-up dosing schedule. You will receive your first full dose of EPKINLY on day 15 of cycle 1. The step-up dosing schedule is when you receive smaller “step-up” doses of EPKINLY on day 1 and day 8 of your first cycle of treatment (cycle 1). Tell your healthcare provider or get medical help right away if you develop symptoms of CRS, including fever of 100.4☏ (38☌) or higher, dizziness or lightheadedness, trouble breathing, chills, fast heartbeat, feeling anxious, headache, confusion, shaking (tremors), or problems with balance and movement, such as trouble walking.ĭue to the risk of CRS, you will receive EPKINLY on a “step-up” dosing schedule. CRS is common during treatment with EPKINLY and can be serious or life-threatening. IMPORTANT SAFETY INFORMATION Important Warnings-EPKINLY can cause serious side effects, including: It is not known if EPKINLY is safe and effective in children.

A study is ongoing to confirm the clinical benefit of EPKINLY. EPKINLY is a prescription medicine used to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma that has come back (relapsed) or that did not respond to previous treatment (refractory), and who have received 2 or more treatments for their cancer.ĮPKINLY is approved based on patient response data.

Patient advocate foundation copay relief